๐ฌ GYN Oncology Intelligence Digest โ Week 2026-W32
GOG 3026 reported ORR 30.6% and median PFS 14.5 months with ribociclib plus letrozole in recurrent low-grade serous ovarian cancer, phase 3 XPORT-EC-042 selinexor maintenance missed its PFS endpoint in TP53 wild-type endometrial cancer, and a Nature study showed ascites lipids block T-cell activation in ovarian cancer.
โก TL;DR
๐ Publications
- Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research. โ All 33 GCIG member groups plus patient advocates, young investigators, low- and middle-income country investigators and the Cervical Cancer Research Network developed and adopted 16 statements across four topic groups
- Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer. โ Analysis covered 39 patients enrolled in two abemaciclib combination trials (letrozole/abemaciclib and letrozole/metformin/abemaciclib, NCT03675893)
๐ฆ Twitter / ๐ฆ Bluesky
- Ovarian cancer ascites lipids block T-cell activation, pointing to shorter CAR T manufacturing โ Lipids in ovarian cancer ascites altered the T cell outer membrane and disrupted how receptors moved, clustered and recycled to the surface, weakening activation without killing the cells
- GOG 3026: ribociclib plus letrozole meets its primary endpoint in recurrent low-grade serous ovarian cancer โ In the phase II GOG 3026 trial, ORR was 30.6% (1 CR, 14 PR) with a clinical benefit rate of 84%
- GCIG pragmatic trials roadmap asks whether gynecologic oncology trials answer the questions patients face โ An international Gynecologic Cancer InterGroup meeting identified priorities including broader eligibility, streamlined procedures, patient-centred outcomes and integration of real-world data
- Molecular classification hierarchy in endometrial cancer: what gets lost when MMRd is outranked โ Endometrial cancer is sorted into four molecular groups โ POLE-mutated, MMRd, p53-abnormal and NSMP โ and the group drives the treatment
- XPORT-EC-042: selinexor maintenance misses its PFS endpoint in TP53 wild-type endometrial cancer โ Phase 3 XPORT-EC-042 missed its PFS primary end point despite a numerical 5.3-month edge
Full details below โ
๐ What's Being Published
Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research. โ Kataria Babita et al., Lancet Oncol
All 33 GCIG member groups, along with patient advocates, young investigators, investigators from low-income and middle-income countries, and the Cervical Cancer Research Network, participated in developing, refining, and adopting 16 statements within four topic groups: diagnosis and staging, early-stage disease, locally advanced disease, and persistent or recurrent disease. The inaugural conference was convened in Dublin, Ireland, on Oct 14โ15, 2024; consensus was obtained for all statements, and areas of unmet need were identified and tabulated.
Clinical bottom line: GCIG now has an agreed 16-statement framework covering diagnosis/staging, early-stage, locally advanced, and recurrent cervical cancer, giving academic trial designers a common global reference point where none existed.
Transcriptional signatures indicating RB function correlate with response to CDK4/6 inhibition in endometrial cancer. โ Yang Zelei et al., Clin Cancer Res
The analysis covered 39 patients enrolled in two abemaciclib combination trials โ letrozole/abemaciclib and letrozole/metformin/abemaciclib (NCT03675893) โ and found that RB protein expression levels and RB1 mutation status did not correlate with CDK4/6 inhibitor response. Instead, decreased activity of multiple RB function-predictive transcriptional signatures, suggesting that RB is functional, corresponded to response; reduced expression of specific E2F family members also correlated with response.
Clinical bottom line: Selecting endometrial cancer patients for CDK4/6 inhibitors by RB1 mutation or RB protein staining is the wrong test; RB function-predictive transcriptional signatures tracked response and should be the basis of future trial eligibility.
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study. โ Harano Kenichi et al., Clin Cancer Res
Patients received olaparib monotherapy 300 mg twice daily for 6 weeks (Cohort 1, n=10) or olaparib plus pembrolizumab 200 mg every 3 weeks for two cycles (Cohort 2, n=20), followed by surgery and platinum-based chemotherapy; ORR was 50.0% (95% CI, 18.7โ81.3) in Cohort 1 and 70.0% (95% CI, 45.7โ88.1) in Cohort 2 (p=0.2839). In Cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%); in Cohort 2, ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non-BRCA1/2-mutated tumors. PD-L1 expression, tumor mutational burden, and microsatellite instability were not associated with response; olaparib monotherapy did not increase tumor immunogenicity, while the combination increased CD8+ T-cell infiltration.
Clinical bottom line: Neoadjuvant olaparib alone produced real radiographic responses in HRD-positive ovarian cancer, and adding pembrolizumab boosted CD8+ infiltration without translating into a clear early response gain, so the immune arm should not move forward on mechanism alone.
๐ฃ๏ธ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
Ovarian cancer ascites lipids block T-cell activation, pointing to shorter CAR T manufacturing
In ovarian cancer ascites, lipids altered the T cell's outer membrane and disrupted how receptors moved, clustered, and recycled back to the cell surface โ weakening the activation signal without killing the cells. One specific lipid, 18:0โ18:2 phosphatidylcholine, reduced T-cell activation, growth, and cancer-killing ability at levels similar to those found in patient ascites. In laboratory experiments, recently activated CAR T cells maintained their cancer-killing ability while older CAR T cells that had returned to a resting state were more easily suppressed, an observation that positions shortened manufacturing as a potential design consideration. Separately, specialized immune cells in the fallopian tube are also being studied as a route to earliest-stage ovarian cancer detection and as a basis for future immunotherapies.
Discussed by: @PatrickHwuMD, @imm.ox.ac.uk
GOG 3026: ribociclib plus letrozole meets its primary endpoint in recurrent low-grade serous ovarian cancer
In the phase II GOG 3026 trial, ribociclib plus letrozole produced an ORR of 30.6% (1 CR, 14 PR), a clinical benefit rate of 84%, a median duration of response of 21.2 months, and a median PFS of 14.5 months; the primary endpoint was met with 15 responses observed against a required threshold of at least 8. Clinicians note these results come from a single-arm phase II study and await confirmation in randomized trials before the combination can be considered a default option in recurrent ER-positive low-grade serous ovarian cancer. In a related context, endometrial cancer work shows that RB protein expression levels and RB1 mutation status do not correlate with CDK4/6 inhibitor response, a finding that may sharpen how biomarker selection is approached across CDK4/6 inhibitor programs in gynecologic cancers.
Discussed by: @ChandrakanthMv, @GOG
GCIG pragmatic trials roadmap asks whether gynecologic oncology trials answer the questions patients face
An international Gynecologic Cancer InterGroup meeting identified priorities including broader eligibility, streamlined procedures, patient-centred outcomes, and integration of real-world data; innovative designs, patient engagement, simplified consent, and responsible AI use were framed as tools to improve trial delivery. The resulting statement is presented as a roadmap to make trials more inclusive, efficient, and relevant to everyday practice. Alongside this, GCIG's inaugural cervical cancer consensus conference โ held with all 33 member groups participating โ adopted 16 statements across four topic groups, providing a parallel example of structured, global trial design coordination.
Discussed by: @OncoAlert, @AinhoaMada
Molecular classification hierarchy in endometrial cancer: what gets lost when MMRd is outranked
Endometrial cancer is now sorted into four molecular groups โ POLE-mutated, MMRd, p53-abnormal, and NSMP โ with the group driving treatment selection. When multiple markers co-occur, a hierarchy of POLE over MMRd over p53 retains only the top classifier; a tumor carrying both POLE mutation and MMRd is filed as POLE, discarding the result that would have pointed toward immunotherapy. The tension is sharpest with MMRd, the one group that is also predictive of immunotherapy benefit. Fertility-sparing treatment in young patients with early endometrial cancer adds further complexity: up to 30% relapse after complete response, and molecular profiling is being proposed to guide patient selection in that setting.
Discussed by: @DrBarbiOnc, @drnutansahu
XPORT-EC-042: selinexor maintenance misses its PFS endpoint in TP53 wild-type endometrial cancer
Phase 3 XPORT-EC-042 missed its PFS primary endpoint despite a numerical 5.3-month edge for selinexor maintenance over placebo. Maintenance selinexor did not improve PFS when used following either chemotherapy alone or chemotherapy plus a checkpoint inhibitor in patients with TP53 wild-type advanced or recurrent endometrial cancer. Whether a numerical 5.3-month difference in a failed phase 3 trial justifies further development of selinexor maintenance in this population remains an open question among oncologists.
Discussed by: @OncLive, @TargetedOnc
๐ฅ Top Ranked Tweets
Gสแดษขแดสส Rษชแดสส @RielyMD
RT @MSKCancerCenter: The @US_FDA recently announced full approval for the drug, selpercatinib (Retevmoยฎ), for treating patients ages 2 and older who have advanced cancer carrying a rare genetic change called RET fusion.
@alexdrilon, a thoracic oncologist and Chief of the Early Drug Development Service at MSK, led one of the two clinical trials that resulted in the FDA granting full approval. Itโs the latest example of treating cancer based on a specific genetic alteration, rather than the location of the tumor.
โThe full FDA approval of selpercatinib marks a pivotal moment in precision oncology โ not simply because it validates this therapy, but also because it extends hope across a broad landscape of tumor types, from lung and thyroid to pancreatic, ovarian, and even rare pediatric tumors,โ says Dr. Drilon.
Dr. Drilon led one of the two clinical trials that resulted in the FDA granting full approval.
Read more about how selpercatinib and the key takeaways: https://t.co/W04HgCup4s
๐ 2 โค๏ธ 22 ๐ 10 ๐ 4,765
CancerTherapyAdvisor @CancerTherAdvsr
New @ASCO guidelines provide new practice recommendations for patients with recurrent platinum-sensitive #OvarianCancer including:
Platinum-based doublet therapy with selective incorporation of bevacizumab, maintenance therapy, and surgical treatment
๐ https://t.co/TJixqL1hlq
๐ 0 โค๏ธ 0 ๐ 0 ๐ 160
In Practice Oncology @inpractice_onc
Phase 3 KEYNOTE-C93 data showed pembrolizumab monotherapy improved PFS vs platinum-doublet chemotherapy in frontline dMMR advanced or recurrent endometrial cancer. Read the findings: https://t.co/R9jcXugPb2
#EndometrialCancer #CommunityOncology #Immunotherapy https://t.co/glJzyIRWFo
๐ 0 โค๏ธ 0 ๐ 0 ๐ 17
Dr. Patrick Hwu @PatrickHwuMD
โ What if T cells are not failing because they are exhausted, but because they cannot properly switch on in the first place?
โก๏ธ In advanced ovarian cancer, fluid called ascitesย can build up in the abdomen. This fluid creates a complex tumor environment filled with cancer cells, immune cells and unusually high levels of fats, or lipids.
Researchers found that some of these lipids can interfere with T cells, the immune cells responsible for recognizing and attacking cancer.
โก๏ธ Normally, receptors on the surface of a T cell gather into tiny clusters when they recognize a threat. This clustering acts like an alarm, activating the T cell so it can multiply, produce cancer-killing molecules and attack its target.
But in ovarian cancer ascites, lipids altered the T cellโs outer membrane and disrupted how those receptors moved, clustered and recycled back to the cell surface. The T cells remained alive, but their activation signal was weakened before they could fully respond.
โก๏ธ The researchers identified one lipid, called 18:0โ18:2 phosphatidylcholine, that reduced T-cell activation, growth and cancer-killing ability at levels similar to those found in patient ascites.
When the researchers removed lipids from the fluid, T-cell signaling and function improved, suggesting that these fats are an important part of the immune-suppressing environment.
โก๏ธ The team also discovered a potential way around this barrier: T cells that were already actively stimulated before entering the ascites continued to function much better.
In laboratory experiments, recently activated #CART cells maintained their cancer-killing ability, while older CAR T cells that had returned to a resting state were more easily suppressed.
๐ก Why this matters:ย This study provides a new explanation for why T-cell therapies have struggled against ovarian cancer. Rather than simply exhausting or killing T cells, tumor-associated lipids may prevent them from properly switching on in the first place.
The findings also suggest that shortening the CAR T-cell manufacturing process, so the cells are infused while they are still highly active, could help them resist this lipid-rich environment.
โจ The big takeaway:ย The environment around a tumor can be just as important as the cancer itself. By understanding how ovarian cancer ascites blocks T-cell activation, researchers may be able to design stronger and more effective cellular therapies. @DJPowellLab @Pennmedicine @Nature @RoddyOConnor @carlhjune @MichaelLDustin @KirOxford @Princeton @UMNews @UniofOxford @PennMedNews @PennMDForum @Penn
๐ Read the study: https://t.co/TfdZaZJl4z
๐ 57 โค๏ธ 99 ๐ 16 ๐ 5,590
Elad Sharon @EladSharonMD
RT @PatrickHwuMD: โ What if T cells are not failing because they are exhausted, but because they cannot properly switch on in the first place?
โก๏ธ In advanced ovarian cancer, fluid called ascitesย can build up in the abdomen. This fluid creates a complex tumor environment filled with cancer cells, immune cells and unusually high levels of fats, or lipids.
Researchers found that some of these lipids can interfere with T cells, the immune cells responsible for recognizing and attacking cancer.
โก๏ธ Normally, receptors on the surface of a T cell gather into tiny clusters when they recognize a threat. This clustering acts like an alarm, activating the T cell so it can multiply, produce cancer-killing molecules and attack its target.
But in ovarian cancer ascites, lipids altered the T cellโs outer membrane and disrupted how those receptors moved, clustered and recycled back to the cell surface. The T cells remained alive, but their activation signal was weakened before they could fully respond.
โก๏ธ The researchers identified one lipid, called 18:0โ18:2 phosphatidylcholine, that reduced T-cell activation, growth and cancer-killing ability at levels similar to those found in patient ascites.
When the researchers removed lipids from the fluid, T-cell signaling and function improved, suggesting that these fats are an important part of the immune-suppressing environment.
โก๏ธ The team also discovered a potential way around this barrier: T cells that were already actively stimulated before entering the ascites continued to function much better.
In laboratory experiments, recently activated #CART cells maintained their cancer-killing ability, while older CAR T cells that had returned to a resting state were more easily suppressed.
๐ก Why this matters:ย This study provides a new explanation for why T-cell therapies have struggled against ovarian cancer. Rather than simply exhausting or killing T cells, tumor-associated lipids may prevent them from properly switching on in the first place.
The findings also suggest that shortening the CAR T-cell manufacturing process, so the cells are infused while they are still highly active, could help them resist this lipid-rich environment.
โจ The big takeaway:ย The environment around a tumor can be just as important as the cancer itself. By understanding how ovarian cancer ascites blocks T-cell activation, researchers may be able to design stronger and more effective cellular therapies. @DJPowellLab @Pennmedicine @Nature @RoddyOConnor @carlhjune @MichaelLDustin @KirOxford @Princeton @UMNews @UniofOxford @PennMedNews @PennMDForum @Penn
๐ Read the study: https://t.co/TfdZaZJl4z
๐ 57 โค๏ธ 99 ๐ 16 ๐ 5,589
MV Chandrakanth @ChandrakanthMv
Ribociclib + Letrozole: A New Benchmark in Recurrent LGSOC?
The phase II GOG 3026 trial adds to the growing evidence supporting CDK4/6 inhibition in recurrent low-grade serous ovarian cancer.
Key findings
โข ORR: 30.6% (1 CR, 14 PR)
โข Clinical benefit rate: 84%
โข Median duration of response: 21.2 months
โข Median PFS: 14.5 months
โข Primary endpoint successfully met (15 responses observed; โฅ8 required)
Clinical perspective
โข Durable responses were observed despite inclusion of patients across multiple prior lines of therapy.
โข Reinforces the biologic rationale for combining endocrine therapy with CDK4/6 inhibition in ER-positive LGSOC.
โข Although encouraging, these results come from a single-arm phase II study and await confirmation in randomized trials.
Slomovitz et al. JCO 2026.
#LGSOC #OvarianCancer #GynOnc #CDK46 #Ribociclib #Letrozole #MedicalOncology #JCO #MVOnco
๐ 11 โค๏ธ 37 ๐ 14 ๐ 2,122
OncoAlert @OncoAlert
RT @scocmem: Important RWD in the emerging post-EVP era: ORR 49% with platinum chemo @ESMO_Open
74% had carbo with similar outcomes โ reassuring given post-EV neuropathy limiting cis.
20% got avelumab โ prospective trials are testing ICI rechallenge.
@OncoAlert
https://t.co/J1i7uNgAju https://t.co/FgMfN4dwnX
๐ 6 โค๏ธ 25 ๐ 13 ๐ 2,935
Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc
Heading to #NRG2026 this weekend, so this feels timely.
#KEYNOTEC93 met its PFS endpoint: pembro monotherapy beat carbo/paclitaxel frontline in dMMR #EndometrialCancer (Merck, July 15, 2026). Real result, but the comparator is chemo alone, not chemo+IO. The #GY018 and #RUBY already moved #dMMR to chemo+IO (HR ~0.30-0.35). Beating chemo alone isnโt the same as matching chemo+IO.
The real clinical question is sequencing: IO first, chemo held in reserve? or chemo+IO first, since pembro (and pembro/lenva) are already approved post-progression regardless of arm. PFS1 doesnโt answer that. PFS2 would, if it was pre-specified and if post-progression therapy was tracked cleanly by arm - neither is confirmed yet.
OS immature, no HR/curves released. Still, a genuine step forward for a chemo-free option in the right patients, and a good sign of how fast this field is moving. Looking forward to digging into the details at NRG.
Merck, July 15, 2026 (KEYNOTE-C93, NCT05173987).
#gyncsm
@NRGonc
๐ 3 โค๏ธ 3 ๐ 0 ๐ 438
Ainhoa Madariaga @AinhoaMada
Delighted to share the results of Study420 at #ESMOGynae2026 @myESMO evaluating Carbo-Mirv in FRฮฑ+ platinum-sensitive #OvarianCancer
๐ฅ N=120. ~50% prior PARPi exposed
๐ Prior PARPi alone did not impact outcomes
๐ Pts progressing during PARPi had โฌ๏ธ ORR &PFS
#gyncsm @OncoAlert https://t.co/JX1JjT0yTR
๐ 2 โค๏ธ 30 ๐ 5 ๐ 1,294
Mali Barbi, MD MSc | Breast & Gyn Oncologist @DrBarbiOnc
#Endometrialcancer isn't one disease. We now sort it into four molecular groups, and the group drives the treatment.
1 #POLE-mutated: excellent prognosis, we're starting to give less.
2 #MMRd (mismatch repair deficient): the group that responds to immunotherapy.
3 #p53-abnormal: the most aggressive, treated hardest.
4 #NSMP: no specific marker, the default.
The groups are meant to be mutually exclusive. But POLE, MMRd, and abnormal p53 can show up in the same tumor. When they do, a rule ranks them, POLE over MMRd over p53, and we keep the top one and set the rest aside.That rule came from small retrospective series where the lower marker looked like a passenger. Fair. But it's a population average turned into a blanket rule, applied to the one tumor in front of you. We don't drop the second marker because we measured it and found it silent here. We drop it because the hierarchy said so. It's sharpest with MMRd, the one group that's also predictive. When POLE outranks it, we file the tumor as POLE and lose the result that would have pointed to immunotherapy. The rule is probably right most of the time. The honest problem is that it's built to never ask when it's wrong.
#gyncsm #gynpath #endometrialcancer
@ESGO_society @NRGonc @GOG @oncodaily
๐ 2 โค๏ธ 12 ๐ 5 ๐ 1,645
IJGC @IJGConline
Phase 3 KEYNOTE-C93 trial results!๐ฅ๐ฅ
#EndometrialCancer
[Quoting @OncoAlert: NEWS FROM INDUSTRY: KEYNOTE-C93 Update in #EndometrialCancer
Source: Merck press release
The Phase 3 KEYNOTE-C93 trial showed pembrolizumab monotherapy significantly improved progression-free survival compared with platinum-based chemotherapy in patients with previously untreated advanced or recurrent endometrial cancer with mismatch repair deficient (dMMR) tumors. The study demonstrated meaningful response rates, complete responses, and durable responses, with a safety profile consistent with prior pembrolizumab studies. Results suggest a potential chemotherapy-free frontline treatment option for this patient population.
https://t.co/1eUPTPKiNh
@agz_eriksson
@ESGO_society
@IJGConline
@NicoloBizzarri
@nataliagandur
@realbowtiedoc
@scocmem
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@Erman_Akkus
@MarioBalsaMD
@DrMirallas
@GIMedOnc
@UOzkerim
@DaisukeKotani
@DraMartinezLago
@p_ciracimd
@amandaNizamMD
@DrVilmaPBarcia]
๐ 2 โค๏ธ 8 ๐ 5 ๐ 2,091
National Cancer Institute @theNCI
NCI researchers have identified genetic subtypes of #CervicalCancer that could help guide more precise therapies and new immunotherapy approaches. https://t.co/jOslBcNJeU https://t.co/Wx0WxFkvek
๐ 1 โค๏ธ 15 ๐ 6 ๐ 1,612
Janice Cowden @JaniceTNBCmets
As ADCs continue moving into the neoadjuvant, adjuvant & earlier #metastatic settings, one of the biggest unanswered โโs is sequencing.
We need evidence to guide what comes next after prior ADC exposure.
This excellent review highlights an important data gap thatโs increasingly relevant to patients, clinicians & researchers alike.
As a member of PCDI (@The_Right_Dose), & #bcsm #patientadvocate, I couldnโt agree more.
https://t.co/DTnTjRDFAX
#ADCs
#MetastaticBreastCancer
#Cancer
@OncoAlert
[Quoting @OncoAlert: ADCs ๐ are already changing cancer treatmentโbut are we getting the next generation right?
Antibodyโdrug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation
This position paper summarizes expert recommendations for advancing antibodyโdrug conjugate (ADC) research and clinical use across solid tumors. ADCs are increasingly standard treatments in #LungCancer ๐ซ , #BreastCancer, #BladderCancer, #OvarianCancer, and #CervicalCancers. Priorities include carefully selecting trials for phase III, developing predictive biomarkers, optimizing ADC constructs and targets, and addressing biomarker heterogeneity. The experts also highlight artificial intelligence as a potential tool to integrate complex datasets and accelerate discovery of composite biomarkers.
@peters_solange
@BanerjeeSusana
@curijoey
@niklas_kluemper
@g_mountzios
@LuisPaz_Ares
@BarbaraPistill2
@tompowles1
@NReguart
@LizzySmyth1
@CharlesSwanton
@LoiSher
@TobiasSchmelzle
@nataliagandur
@realbowtiedoc
@FernandoOnco
@ElisaAgostinett
@to_be_elizabeth
@MarioBalsaMD
@BRicciutiMD
@HHorinouchi
@UOzkerim
@p_ciracimd
@AmandaNizamMD
@scocmem
@DrVilmaPBarcia
@DraMartinezLago
@DrMirallas
@GIMedOnc]
๐ 1 โค๏ธ 11 ๐ 6 ๐ 1,248
Targeted Oncology @TargetedOnc
๐ฌ Interim data from KEYNOTE-C93 shows pembrolizumab monotherapy demonstrated a PFS benefit over platinum doublet chemotherapy in the frontline setting for dMMR advanced or recurrent #EndometrialCancer.
Read more: https://t.co/zEf3wtJFgY
#GynOnc #Oncology
๐ 1 โค๏ธ 3 ๐ 0 ๐ 271
Lilly Oncology Medical @LillyOncMed
๐ฌFRAmework-01 | Now Enrolling
A phase 3 trial evaluating a FRฮฑ-targeting ADC in patients with #OvarianCancer.
Key details:
โ Enrolling PSOC and PROC
โ All FRฮฑ expression levels
โ Allows prior mirvetuximab
๐Click here for trial & enrollment info: https://t.co/ZfOPciVDfA
#GYNOnc
๐ 1 โค๏ธ 1 ๐ 0 ๐ 115
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
Know a colleague who would find this useful? Just forward them this email.